Tanabe Pharma Corporation: Hepatitis C, Chronic trials

The registry lists 11 Hepatitis C, Chronic studies with Tanabe Pharma Corporation as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 1Phase 3 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedNCT01753570Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedNCT01753557Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsCompletedNCT01468584Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsCompletedNCT01466192Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based TherapyCompletedNCT00780910Phase 3Results posted
• Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis CCompletedNCT00780416Phase 3Results posted
• A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis CCompletedNCT00630058Phase 1Results posted
• Safety and Efficacy of MP-424 to Treat Chronic Hepatitis CCompletedNCT00621296Phase 2Results posted
• Safety and PK Study of MP-424 to Treat Chronic Hepatitis CCompletedNCT00591214Phase 1Results posted
• Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis CCompletedNCT00200343Phase 3Results posted
• Clinical Pharmacology Study of MP-424CompletedNCT01766167Phase 1